Malignant pleural mesothelioma (MPM) is an asbestos-related cancer for which Australia and New Zealand have among the world’s highest incidence rates. This aggressive cancer has poor prognosis and no curative treatments. Although associated with asbestos exposure, the carcinogenic mechanism in MPM is only partly understood, and no preventive measures have been successful. In this talk I will present our research into the molecular biology of MPM, with a focus on aberrant microRNA expression. This work led to the first clinical trial of microRNA replacement in thoracic cancer patients, and is an approach with the potential to improve outcomes in patients.
|Date||Tuesday, 17 April 2018|
|Time||12:00pm - 1:00pm|
|Event Category||Health Sciences|
|Department||Pathology (DSM), Pathology|
|Location||D'ath Lecture Theatre, Hercus Building.|
|Contact Name||Dr Euan Rodger|